Sanofi–Aventis Merger

B. Rajesh Kumar
Additional contact information
B. Rajesh Kumar: Institute of Management Technology

Chapter 32 in Wealth Creation in the World’s Largest Mergers and Acquisitions, 2019, pp 277-280 from Springer

Abstract: Abstract In the year 2004 after a bitter takeover battle, France’s largest drug maker, Aventis, agreed to be absorbed by a smaller rival company Sanofi-Synthelabo SA in a cash and stock deal valued for Euro 55.2 billion ($65 billion). At the time of the deal, the consolidation created the world’s third largest pharmaceutical company with a market capitalization of approximately 90 billion euros behind US-based Pfizer and Britain’s GlaxoSmithKline. The French government put pressure on Sanofi-Synthelabo to raise its bid for Aventis and for Aventis to accept the offer. Under the terms of the revised bid, Sanofi offered five of its shares for each Aventis shares held plus €120 in cash. During the −78 to +173 (254-day merger period) covering January 1, 2004–January 2005, the Aventis stock gained 9.20% on cumulative basis.

Keywords: Shared Assertion; Drug Makers; Cumulative Basis; Large Pharmaceutical Companies; Announcement Period Returns (search for similar items in EconPapers)
Date: 2019
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:mgmchp:978-3-030-02363-8_32

Ordering information: This item can be ordered from
http://www.springer.com/9783030023638

DOI: 10.1007/978-3-030-02363-8_32

Access Statistics for this chapter

More chapters in Management for Professionals from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().